Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study

BACKGROUND: Febuxostat immediate release (IR), a xanthine oxidase inhibitor, is indicated for the management of hyperuricemia in patients with gout by lowering urate levels. An extended release (XR) formulation of febuxostat was developed to provide equal or superior efficacy on urate lowering compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunawardhana, Lhanoo, Becker, Michael A., Whelton, Andrew, Hunt, Barbara, Castillo, Majin, Saag, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977466/
https://www.ncbi.nlm.nih.gov/pubmed/29848361
http://dx.doi.org/10.1186/s13075-018-1593-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977466/
https://www.ncbi.nlm.nih.gov/pubmed/29848361
http://dx.doi.org/10.1186/s13075-018-1593-0

Ejemplares similares